Lasa Supergenerics Ltd vs Shukra Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 10, 2026

Key Highlights

The Latest Trading Price of Lasa Supergenerics Ltd is ₹ 8.37 as of 08 May 15:30 . The P/E Ratio of Lasa Supergenerics Ltd changed from 10.7 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Shukra Pharmaceuticals Ltd changed from 37.1 on March 2021 to 99.3 on March 2025 . This represents a CAGR of 21.76% over 5 years The Market Cap of Lasa Supergenerics Ltd changed from ₹ 243.63 crore on March 2021 to ₹ 84.42 crore on March 2025 . This represents a CAGR of -19.10% over 5 yearsThe Market Cap of Shukra Pharmaceuticals Ltd changed from ₹ 6.97 crore on March 2021 to ₹ 956.77 crore on March 2025 . This represents a CAGR of 167.62% over 5 years The revenue of Lasa Supergenerics Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Shukra Pharmaceuticals Ltd for the Mar '26 is ₹ 7.27 crore as compare to the Dec '25 revenue of ₹ 39.95 crore. This represent the decline of -81.8% The ebitda of Lasa Supergenerics Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Shukra Pharmaceuticals Ltd for the Mar '26 is ₹ 1.65 crore as compare to the Dec '25 ebitda of ₹ 27.95 crore. This represent the decline of -94.1% The net profit of Lasa Supergenerics Ltd changed from ₹ 0 crore to ₹ 0 crore over 6 quarters. This represents a CAGR of 0.0% The net profit of Shukra Pharmaceuticals Ltd changed from ₹ 3.16 crore to ₹ -1.72 crore over 6 quarters. This represents a CAGR of NaN% The Dividend Payout of Lasa Supergenerics Ltd changed from 4.46 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Shukra Pharmaceuticals Ltd changed from 10.47 % on March 2022 to 4.57 % on March 2025 . This represents a CAGR of -18.72% over 4 years .

About Lasa Supergenerics Ltd

Lasa Supergenerics Limited was incorporated on March 11, 2016.
The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc. The Company is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing.
The Company is a veterinary API manufacturing entity, which was acquired in April, 2012.
The manufacturing facility is located at Mahad & Chiplun, in the Konkan region of Maharashtra.
It specialises in catalyst chemistry' and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India.

About Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Limited, formerly known Relish Pharmaceuticals Limited was established in March, 1993 and later on the Company name was changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on September 22, 2016.
The Company is presently engaged in the business of manufacturing and trading of pharmaceuticals formulations and laboratory testing. The company provides varieties of products to the clientele.
Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.

FAQs for the comparison of Lasa Supergenerics Ltd and Shukra Pharmaceuticals Ltd

Which company has a larger market capitalization, Lasa Supergenerics Ltd or Shukra Pharmaceuticals Ltd?

Market cap of Lasa Supergenerics Ltd is 41 Cr while Market cap of Shukra Pharmaceuticals Ltd is 1,468 Cr

What are the key factors driving the stock performance of Lasa Supergenerics Ltd and Shukra Pharmaceuticals Ltd?

The stock performance of Lasa Supergenerics Ltd and Shukra Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Lasa Supergenerics Ltd and Shukra Pharmaceuticals Ltd?

As of May 10, 2026, the Lasa Supergenerics Ltd stock price is INR ₹8.37. On the other hand, Shukra Pharmaceuticals Ltd stock price is INR ₹33.54.

How do dividend payouts of Lasa Supergenerics Ltd and Shukra Pharmaceuticals Ltd compare?

To compare the dividend payouts of Lasa Supergenerics Ltd and Shukra Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.